Cheng Shu-qun, Wu Meng-chao, Chen Han, Shen Feng, Yang Jia-he, Cong Wen-ming, Wang Pei-jun, Zhao Yu-xiang
Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai 200438, China.
Zhonghua Yi Xue Za Zhi. 2004 Jan 2;84(1):3-5.
To evaluate the benefit of typing of tumor thrombi in determining treatment plan and assessing prognosis of hepatocellular carcinoma (HCC) with tumor thrombi in the portal vein.
The clinical data of 84 patients of HCC with portal vein tumor thrombi admitted from Jan. 2000 to Jan. 2003 were analyzed retrospectively. The patients, 75 males and 9 females, aged 47 (28 - 70), were divided into 4 groups, groups I - IV, according to imaging examination of the tumor thrombi. The median survival periods and effectiveness of treatment, including surgical resection and non-surgical treatment, were observed.
The surgical resection rates were 64.7%, 83.8%, 31.4%, and 0 in the groups I - IV respectively (P = 0.912). The general median survival period of the patients undergoing surgery was 8.0 months, significantly longer than that of the patients receiving non-surgical treatment (4.0 months, P = 0.000 6). In different group of tumor thrombi type, the general median survival period of the patients undergoing surgery was significantly longer than that of the patients receiving non-surgical treatment. The median survival periods were 10.1, 7.2, 5.7 and 3.0 months for groups I (n = 17), II (n = 26), III (n = 35) and groups IV (n = 6) respectively, with significant difference between any 2 groups (all P = 0.000 1).
Typing of tumor thrombi helps determine the treatment plan and assess the prognosis of hepatocellular carcinoma patients with tumor thrombi in the portal vein.
评估肿瘤血栓分型在确定治疗方案及评估门静脉癌栓型肝细胞癌(HCC)预后中的作用。
回顾性分析2000年1月至2003年1月收治的84例门静脉癌栓型HCC患者的临床资料。患者年龄47(28 - 70)岁,男75例,女9例,根据肿瘤血栓的影像学检查分为Ⅰ - Ⅳ组。观察手术切除和非手术治疗的中位生存期及疗效。
Ⅰ - Ⅳ组手术切除率分别为64.7%、83.8%、31.4%和0(P = 0.912)。手术患者总体中位生存期为8.0个月,显著长于非手术治疗患者(4.0个月,P = 0.000 6)。在不同肿瘤血栓类型组中,手术患者总体中位生存期显著长于非手术治疗患者。Ⅰ组(n = 17)、Ⅱ组(n = 26)、Ⅲ组(n = 35)和Ⅳ组(n = 6)的中位生存期分别为10.1、7.2、5.7和3.0个月,任意两组间差异均有统计学意义(均P = 0.000 1)。
肿瘤血栓分型有助于确定门静脉癌栓型肝细胞癌患者的治疗方案并评估其预后。